Novo's Victoza hits another FDA speed bump

Novo Nordisk's diabetes drug Victoza has run into another speed bump at the FDA. The Danish biotech says that the FDA's formal feedback on the drug has been delayed beyond the end of the year. But the company adds that a response is expected in a matter of weeks. The closely-watched diabetes drug, also called liraglutide, has been approved in Europe but has faced repeated delays in the U.S.

"Formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1 analogue, is expected within weeks," Novo Nordisk says in a statement. "Novo Nordisk continues the constructive dialogue with the FDA regarding the regulatory process for liraglutide."

- read Novo's release
- here's the story from Reuters

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.